(Q33410997)

26 July 2017

title

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma (English)

1 reference

26 July 2017

James R Berenson

1

1 reference

26 July 2017

James D Hilger

2

1 reference

26 July 2017

Ori Yellin

3

1 reference

26 July 2017

Ralph V Boccia

4

1 reference

26 July 2017

Jeffrey Matous

5

1 reference

26 July 2017

Kenneth Dressler

6

1 reference

26 July 2017

Hassan H Ghazal

7

1 reference

26 July 2017

Saad Jamshed

8

1 reference

26 July 2017

Edwin C Kingsley

9

1 reference

26 July 2017

Wael A Harb

10

1 reference

26 July 2017

Stephen J Noga

11

1 reference

26 July 2017

Youram Nassir

12

1 reference

26 July 2017

Regina A Swift

13

1 reference

26 July 2017

Robert Vescio

14

1 reference

26 July 2017

publication date

18 October 2013

1 reference

26 July 2017

1 reference

26 July 2017

volume

93

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

89-98

1 reference

The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Emerging therapies for the treatment of relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Unraveling the epigenetic code of cancer for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

From the bench to the bedside: emerging new treatments in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Clinical studies of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Vorinostat enhances the antimyeloma effects of melphalan and bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1910-2

10.1007/S00277-013-1910-2

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference